van den Bosch, Tom http://orcid.org/0000-0002-5266-8446
Rueda, Oscar M. http://orcid.org/0000-0003-0008-4884
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
Vermeulen, Louis http://orcid.org/0000-0002-6066-789X
Miedema, Daniƫl M. http://orcid.org/0000-0002-0729-3753
Funding for this research was provided by:
Amsterdam UMC, Oncode, Amsterdam Gastroenterology & Metabolism
Amsterdam UMC, Oncode, Amsterdam Gastroenterology & Metabolism
KWF Kankerbestrijding (12215)
Amsterdam UMC, Oncode, Amsterdam Gastroenterology & Metabolism
Article History
Received: 19 January 2022
Revised: 22 June 2022
Accepted: 28 June 2022
First Online: 21 July 2022
Competing interests
: LV and DMM are listed as inventors in a pending patent application (PCT/EP2021/04963) filed by Oncode Institute on behalf of the Academisch Medisch Centrum, describing CNH and the application of CNH to stratify the risk of cancer patients.
: This is a retrospective study of previously published data.
: Not applicable.